Current Research Interests
My work uses a variety of experimental and analytical approaches to define and characterize genetic subsets of lung cancer with the goal of identifying novel precision treatment approaches for lung cancer patients. Specifically, my previous work has characterized gene expression profiles, signaling pathways, and drug sensitivity patterns that define lung adenocarcinomas that have lost the LKB1 tumor suppressor. This gene, a serine-threonine kinase also known as STK11, is lost in approximately 30% of lung adenocarcinomas and is known to inhibit the oncogenic mTOR pathway through the interaction of LKB1 with its downstream target, AMPK. Because it is a tumor suppressor, with activity that cannot be easily restored or directly targeted with drugs, identifying novel therapies is dependent on using these integrated molecular approaches to study its effects on tumor biology. My current work seeks to 1) determine novel clinical targets and 2) discover mechanisms of resistance to immune checkpoint inhibition in LKB1 deficient lung cancer, using a high-throughput CRISPR-CAS9 screening approach.
Current Appointments & Affiliations
Some information on this profile has been compiled automatically from
Duke databases and external sources. (Our
About page explains how this works.)
If you see a problem with the information, please write to
Scholars@Duke and let us know. We will